Targeting key players of neuroendocrine differentiation in prostate cancer
Fecha
2023Versión
Acceso abierto / Sarbide irekia
Tipo
Artículo / Artikulua
Versión
Versión publicada / Argitaratu den bertsioa
Identificador del proyecto
Impacto
|
10.3390/ijms241813673
Resumen
Neuroendocrine prostate cancer (NEPC) is a highly aggressive subtype of prostate cancer (PC) that commonly emerges through a transdifferentiation process from prostate adenocarcinoma and evades conventional therapies. Extensive molecular research has revealed factors that drive lineage plasticity, uncovering novel therapeutic targets to be explored. A diverse array of targeting agents is currentl ...
[++]
Neuroendocrine prostate cancer (NEPC) is a highly aggressive subtype of prostate cancer (PC) that commonly emerges through a transdifferentiation process from prostate adenocarcinoma and evades conventional therapies. Extensive molecular research has revealed factors that drive lineage plasticity, uncovering novel therapeutic targets to be explored. A diverse array of targeting agents is currently under evaluation in pre-clinical and clinical studies with promising results in suppressing or reversing the neuroendocrine phenotype and inhibiting tumor growth and metastasis. This new knowledge has the potential to contribute to the development of novel therapeutic approaches that may enhance the clinical management and prognosis of this lethal disease. In the present review, we discuss molecular players involved in the neuroendocrine phenotype, and we explore therapeutic strategies that are currently under investigation for NEPC. [--]
Materias
Lineage plasticity,
Neuroendocrine transdifferentiation,
Prostate cancer,
Targeted therapy
Editor
MDPI
Publicado en
International Journal of Molecular Sciences 2023, 24(18), 13673
Departamento
Universidad Pública de Navarra. Departamento de Ciencias de la Salud /
Nafarroako Unibertsitate Publikoa. Osasun Zientziak Saila
Versión del editor
Entidades Financiadoras
This research was funded by: The Spanish Ministry of Science, Innovation and Universities, grant number: PID2019-109577RA-I00/AEI/10.13039/501100011033; The Spanish Ministry of Science, Innovation and Universities (Ramón y Cajal Program), grant number: RYC-2018-023874-I (M.R.); The Department of Health, Government of Navarre, grant number: 026/2022.